Shield Therapeutics (LON:STX)‘s stock had its “buy” rating reaffirmed by Peel Hunt in a research note issued on Tuesday, ThisIsMoney.Co.Uk reports.

STX has been the subject of several other reports. FinnCap reaffirmed a “corporate” rating on shares of Shield Therapeutics in a report on Monday, January 27th. Peel Hunt reaffirmed a “buy” rating and set a GBX 200 ($2.63) target price on shares of Shield Therapeutics in a report on Wednesday, January 8th.

Shares of LON:STX traded down GBX 0.50 ($0.01) during trading on Tuesday, hitting GBX 54 ($0.71). 4,099,314 shares of the stock traded hands, compared to its average volume of 48,665. The company has a quick ratio of 4.57, a current ratio of 4.79 and a debt-to-equity ratio of 0.26. The company has a market cap of $62.11 million and a price-to-earnings ratio of 15.00. The company has a fifty day moving average price of GBX 141.91 and a two-hundred day moving average price of GBX 171.34. Shield Therapeutics has a 52-week low of GBX 60 ($0.79) and a 52-week high of GBX 202 ($2.66).

Shield Therapeutics Company Profile

Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.

Featured Story: What is the Russell 2000 Index?

Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.